Erin Delmore is a dynamic Lead Global Study Manager at Sanofi Genzyme, where she leverages her extensive experience in clinical research to drive the operational success of high-profile clinical trials. With a strong foundation in clinical study management, Erin is adept at overseeing all aspects...
Erin Delmore is a dynamic Lead Global Study Manager at Sanofi Genzyme, where she leverages her extensive experience in clinical research to drive the operational success of high-profile clinical trials. With a strong foundation in clinical study management, Erin is adept at overseeing all aspects of clinical trial operations, ensuring that each study is delivered on time, within budget, and in strict compliance with Good Clinical Practices (GCP), standard operating procedures (SOPs), and regulatory standards.
Currently, Erin is at the helm of a significant global study focused on Autosomal Dominant Polycystic Kidney Disease (ADPKD), where she coordinates a multinational team of professionals. Her role involves meticulous project implementation, from forecasting timelines to managing resources effectively, which is essential for navigating the complexities of clinical trials in the life sciences sector. Erin's ability to build and maintain positive, lasting relationships with study teams, monitors, vendors, and investigative site staff is a testament to her strong interpersonal skills and commitment to collaboration.
In addition to her project management expertise, Erin is well-versed in utilizing electronic data capture (EDC) systems and digital imaging technologies, which enhance data integrity and streamline study processes. Her comprehensive understanding of regulatory requirements, including those set forth by the U.S. Food and Drug Administration (FDA), ensures that all studies adhere to the highest standards of quality and compliance. With a proven track record of meeting tight project deliverables, Erin Delmore continues to make significant contributions to the advancement of clinical research at Sanofi Genzyme.
